IMMUNE RECONSTITUTION AFTER
CAR-T: WHAT TO EXPECT

CAR-T therapy works by reprogramming the patient's T cells to recognise and destroy cancer cells carrying a specific antigen — most commonly CD19 in B-cell lymphomas, leukaemias, and selected other cancers. The same therapy also affects healthy cells carrying that antigen. CD19, for example, is also found on normal B cells, the cells that produce antibodies. As CAR-T cells eliminate cancerous B cells, they also eliminate healthy B cells, leaving patients with low B-cell counts (B-cell aplasia) and reduced antibody production (hypogammaglobulinaemia) for months to years. This is expected and managed with supportive care, not a sign that something has gone wrong.

Weeks 1 to 4: early recovery Cytopenias — low neutrophil, platelet, and red cell counts — are common and may persist or worsen during this window. Granulocyte colony-stimulating factor (G-CSF), platelet transfusions, red cell transfusions, and infection prophylaxis are routinely used. Patients are usually asked to remain near the treating centre for ongoing monitoring. Energy levels are low, appetite is variable, and rest is essential. Months 1 to 3: stabilisation Most patients see gradual improvement in blood counts, although prolonged neutropenia and thrombocytopenia can persist in some. B-cell aplasia and low IgG levels become the dominant immune issue. IVIG replacement is typically started or continued. Antimicrobial prophylaxis — covering Pneumocystis pneumonia, herpes viruses, and sometimes fungal pathogens — is standard. Energy returns slowly, and patients can usually resume light daily activities. Months 3 to 6: ongoing recovery Blood counts usually normalise in most patients during this window. B-cell aplasia and hypogammaglobulinaemia continue, with IVIG given monthly or as needed based on IgG levels and infection history. Vaccinations may begin around six months post-CAR-T at experienced centres, starting with inactivated vaccines. Live vaccines are usually deferred until B-cell recovery is documented. Months 6 to 12: gradual normalisation Many patients recover B cells during this window, although some continue with B-cell aplasia for longer — particularly those with persistent CAR-T cell activity. Inactivated vaccinations continue per protocol. Energy and quality of life often improve substantially. Patients typically return to work, school, or normal activities, with infection precautions adjusted to the situation. Beyond one year: late effects monitoring Long-term monitoring focuses on durability of cancer remission, late infections, secondary malignancies (rare but reported), endocrine effects, cardiac and pulmonary surveillance where relevant, and resumption of any deferred vaccinations. Most patients live well, but structured follow-up continues for years. Annual review at the treating centre or with a coordinated home oncology team is standard.

Infection is the dominant medical concern during immune reconstitution. The risk is highest in the first three months and decreases gradually thereafter. Common issues include bacterial infections during periods of neutropenia, viral reactivations such as CMV and herpes simplex, and respiratory infections including influenza, RSV, and COVID-19. Standard preventive measures include antibacterial, antiviral, and Pneumocystis prophylaxis as per centre protocol, IVIG replacement to maintain antibody levels, careful hand hygiene and infection precautions at home, and avoiding contact with people who are unwell or recently vaccinated with live vaccines. Patients should report any fever above 38°C immediately, even months after CAR-T.

Intravenous immunoglobulin replacement is one of the most important elements of post-CAR-T care. IVIG provides ready-made antibodies that compensate for the patient's reduced ability to produce them during B-cell aplasia. Most patients receive IVIG monthly, with dose and frequency adjusted to IgG levels (typically maintained above 4–6 g/L) and infection history. Subcutaneous immunoglobulin (SCIG) is an alternative that some patients self-administer at home. IVIG is generally well tolerated, with mild infusion reactions managed by slowing the rate or pre-medication. Continuing IVIG access after returning home is one of the most important continuity-of-care issues for international patients.

Most vaccines given before CAR-T lose their effectiveness because the antibody-producing B cells have been depleted. A structured re-vaccination programme is essential and is usually started around six months after CAR-T at experienced centres. Inactivated vaccines come first — influenza, pneumococcal, hepatitis B, tetanus-diphtheria-pertussis, COVID-19, and others according to local guidelines. Live attenuated vaccines (MMR, varicella, yellow fever) are typically deferred until at least one year post-CAR-T and only given after B-cell recovery is confirmed. Vaccination plans should be made in coordination between the treating centre and the home oncology team, particularly for international patients.

Continuity planning — before international patients return home, a structured post-CAR-T plan covering IVIG access, prophylaxis, blood count monitoring, and follow-up imaging is coordinated with the home oncology team. Communication with treating centre — questions, monitoring results, and complications during recovery are channelled to the original treating team for guidance, avoiding fragmented care. Home team coordination — where the home oncology team is unfamiliar with post-CAR-T management, CancerFax helps share protocols, vaccination plans, and supportive care guidance. Late effect surveillance — annual review schedules and coordination of disease monitoring, infection management, and any required interventions are supported through a single point of contact.

Frequently Asked Questions

Answers to common questions from patients and families.